Art. -Nr.: HY-155115

LSD1-IN-27

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

LSD1-IN-27 is an orally active LSD1 inhibitor (IC₅₀: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.88%
CAS. Nr.: 2904571-94-2
Formel: C₂₄H₂₅N₃
Molecular Weight:355.48

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

LSD1-IN-27 Chemical Structure

CAS. Nr.: 2904571-94-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

13 nM (LSD1)^[1]

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen :

In Vitro

LSD1-IN-27 (Compound 5ac; 1-2 μM; 24-48 h) reduces the stemness and migration ability of gastric cancer cells^[1].
LSD1-IN-27 (1-2 μM; 5 days) induces the accumulation of LSD1 substrate H3K4me1 and H3K4me2 in BGC-823 cells^[1].
LSD1-IN-27 (1-2 μM; 5 days) suppresses the expression of PD-L1 and promoted T-cell killing response of gastric cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[1]

Cell Line:

BGC-823 gastric cancer cells.
Concentration:

1 μM, 2 μM
Incubation Time:

24 h, 48 h
Result:

Can effectively reduce the stemness and migration ability of gastric cancer cells.

RT-PCR^[1]

Cell Line:

BGC-823 gastric cancer cells.
Concentration:

1 μM, 2 μM
Incubation Time:

5 days
Result:

The mRNA level of PD-L1 was reduced.

Western Blot Analysis^[1]

Cell Line:

BGC-823 gastric cancer cells.
Concentration:

1 μM, 2 μM
Incubation Time:

5 days
Result:

Can induce the accumulation of LSD1 substrate H3K4me1 and H3K4me2.
Inhibited the expression of CD44, OCT4, SOX2, and Nanog.

In Vivo

LSD1-IN-27 (Compound 5ac; 15-50 mg/kg; p.o.; daily ; for 14 consecutive days) is highly effective in inhibiting tumor cell growth and has minimal toxicity in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male 615 mice (15-20 g; 4-5 weeks) were subcutaneously injected MFC cells into the right axilla^[1].
Dosage:

15 mg/kg, 25 mg/kg, 50 mg/kg
Administration:

Administered by gavage; daily ; for 14 consecutive days
Result:

The mice showed little change in body weight and no significant liver or kidney damage.
Inhibited the tumor growth of MFC cells in vivo in a dose-dependent manner.

Chemical Information

CAS. Nr. 2904571-94-2
Appearance Solid
Molecular Weight 355.48
Formel C₂₄H₂₅N₃
Color Yellow to orange
SMILES

CC1=CC=C2C(C(NC3=CC=C(N(C)C)C=C3)=C4C(C(C)=C(C)C=C4)=N2)=C1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Sci Rep

Discovery of natural apigenin analogues as lysine-specific demethylase 1 inhibitors against tumoral testicular germ cells. [Abstract]

2026 Mar 2;16(1):8917. PMID: 41772063

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (281.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8131 mL

14.0655 mL

28.1310 mL

5 mM

0.5626 mL

2.8131 mL

5.6262 mL

10 mM

0.2813 mL

1.4065 mL

2.8131 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Dai XJ, et al. Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer. Eur J Med Chem. 2023 Nov 5;259:115684. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8131 mL	14.0655 mL	28.1310 mL	70.3274 mL
	5 mM	0.5626 mL	2.8131 mL	5.6262 mL	14.0655 mL
	10 mM	0.2813 mL	1.4065 mL	2.8131 mL	7.0327 mL
	15 mM	0.1875 mL	0.9377 mL	1.8754 mL	4.6885 mL
	20 mM	0.1407 mL	0.7033 mL	1.4065 mL	3.5164 mL
	25 mM	0.1125 mL	0.5626 mL	1.1252 mL	2.8131 mL
	30 mM	0.0938 mL	0.4688 mL	0.9377 mL	2.3442 mL
	40 mM	0.0703 mL	0.3516 mL	0.7033 mL	1.7582 mL
	50 mM	0.0563 mL	0.2813 mL	0.5626 mL	1.4065 mL
	60 mM	0.0469 mL	0.2344 mL	0.4688 mL	1.1721 mL
	80 mM	0.0352 mL	0.1758 mL	0.3516 mL	0.8791 mL
	100 mM	0.0281 mL	0.1407 mL	0.2813 mL	0.7033 mL

Keywords

LSD1-IN-27

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

LSD1-IN-27

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) LSD1-IN-27

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LSD1-IN-27

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) LSD1-IN-27

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LSD1-IN-27 Related Classifications

Art. -Nr.: HY-155115